Biosynex Total Liabilities
Biosynex total liabilities. Based on the latest financial reports, Biosynex (ALBIO) has total liabilities worth €105.13 Million EUR (≈ $122.91 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Biosynex's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Biosynex (2006–2024)
Total liabilities of Biosynex from 2006 to 2024. This chart illustrates how Biosynex's total liabilities have evolved over time, based on quarterly financial data. Explore Biosynex long-term investment intensity to see how much of total assets are deployed in long-term investments.
Biosynex Competitors by Total Liabilities
The table below lists competitors of Biosynex ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Atta Global Group Bhd
KLSE:7099
|
Malaysia | RM45.13 Million |
|
Heavy Minerals Ltd
AU:HVY
|
Australia | AU$3.53 Million |
|
Rajshree Polypack Limited
NSE:RPPL
|
India | Rs1.62 Billion |
|
SeaTwirl AB
ST:STW
|
Sweden | Skr71.95 Million |
|
ATP 30 Public Company Limited
BK:ATP30
|
Thailand | ฿667.54 Million |
|
Mercer International Inc
F:AEZ
|
Germany | €1.97 Billion |
|
Energean Oil & Gas PLC
LSE:ENOG
|
UK | GBX3.13 Billion |
|
Clean Seas Seafood Limited
F:C7S
|
Germany | €25.00 Million |
Liability Composition Analysis (2006–2024)
This chart breaks down Biosynex's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Biosynex assets under control.
Liquidity & Leverage Metrics
Biosynex Total Liabilities Ratios Explained
Biosynex total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.70 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biosynex's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biosynex (2006–2024)
The table below shows the annual total liabilities of Biosynex from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €114.19 Million ≈ $133.50 Million |
-2.74% |
| 2023-12-31 | €117.41 Million ≈ $137.27 Million |
+25.96% |
| 2022-12-31 | €93.21 Million ≈ $108.98 Million |
-7.84% |
| 2021-12-31 | €101.14 Million ≈ $118.24 Million |
+69.17% |
| 2020-12-31 | €59.78 Million ≈ $69.89 Million |
+252.37% |
| 2019-12-31 | €16.97 Million ≈ $19.84 Million |
+66.35% |
| 2018-12-31 | €10.20 Million ≈ $11.92 Million |
-12.10% |
| 2017-12-31 | €11.60 Million ≈ $13.57 Million |
-23.39% |
| 2016-12-31 | €15.15 Million ≈ $17.71 Million |
+122.01% |
| 2015-12-31 | €6.82 Million ≈ $7.98 Million |
+103.94% |
| 2014-12-31 | €3.35 Million ≈ $3.91 Million |
-0.24% |
| 2013-12-31 | €3.35 Million ≈ $3.92 Million |
-8.63% |
| 2012-12-31 | €3.67 Million ≈ $4.29 Million |
+297.02% |
| 2011-12-31 | €924.34K ≈ $1.08 Million |
-1.96% |
| 2010-12-31 | €942.86K ≈ $1.10 Million |
-2.39% |
| 2009-12-31 | €965.95K ≈ $1.13 Million |
+32.14% |
| 2008-12-31 | €731.01K ≈ $854.63K |
+47.38% |
| 2007-12-31 | €496.00K ≈ $579.88K |
+16.98% |
| 2006-12-31 | €424.00K ≈ $495.70K |
-- |
About Biosynex
Biosynex SA designs, manufactures, and distributes rapid diagnostic tests to patients and healthcare professionals in France and internationally. The company develops and markets IVDs in the form of RDTs and TRODs, immunoblot, molecular biology, and POC for screening, diagnosis, and prevention. It also provides thermometers, tensiometers, oximetry, hearing protection products, oral and dental hyg… Read more